• 1238 Citations
  • 14 h-Index
19982019
If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where G. Ostoros is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 11 Similar Profiles
Non-Small Cell Lung Carcinoma Medicine & Life Sciences
Lung Neoplasms Medicine & Life Sciences
Epidermal Growth Factor Receptor Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Mutation Medicine & Life Sciences
gemcitabine Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Small Cell Lung Carcinoma Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1998 2019

  • 1238 Citations
  • 14 h-Index
  • 52 Article
  • 1 Comment/debate
  • 1 Review article
2 Citations (Scopus)

Efficacy and safety of the biosimilar ABP 215 compared with bevacizumab in patients with advanced nonsquamous non–small cell lung cancer (MAPLE): A randomized, double-blind, phase III study

Thatcher, N., Goldschmidt, J. H., Thomas, M., Schenker, M., Pan, Z., Rodriguez, L. P. A., Breder, V., Ostoros, G. & Hanes, V., Apr 1 2019, In : Clinical Cancer Research. 25, 7, p. 2088-2095 8 p.

Research output: Contribution to journalArticle

Open Access
Biosimilar Pharmaceuticals
Non-Small Cell Lung Carcinoma
Safety
Odds Ratio
Pharmacokinetics

Erratum: Efficacy and safety of the biosimilar ABP 215 compared with bevacizumab in patients with advanced nonsquamous non–small cell lung cancer (MAPLE): A randomized, double-blind, phase III study (Clin Cancer Res (2019) 25(2088–95)Doi:10.1158/1078-0432.CCR-18-2702)

Thatcher, N., Goldschmidt, J. H., Thomas, M., Schenker, M., Pan, Z., Paz-Ares Rodriguez, L., Breder, V., Ostoros, G. & Hanes, V., Jan 1 2019, In : Clinical Cancer Research. 25, 10, 1 p.

Research output: Contribution to journalComment/debate

Open Access
Biosimilar Pharmaceuticals
Non-Small Cell Lung Carcinoma
Safety
Neoplasms
Emotions

Erlotinib as single agent first line treatment in locally advanced or metastatic activating EGFR mutation-positive lung adenocarcinoma (CEETAC): An open-label, non-randomized, multicenter, phase IV clinical trial

Markóczy, Z., Sárosi, V., Kudaba, I., Gálffy, G., Turay, Ü. Y., Demirkazik, A., Purkalne, G., Somfay, A., Pápai-Székely, Z., Rásó, E. & Ostoros, G., May 25 2018, In : BMC Cancer. 18, 1, 598.

Research output: Contribution to journalArticle

Phase IV Clinical Trials
Epidermal Growth Factor Receptor
Mutation
Disease-Free Survival
Safety